{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:26:10Z","timestamp":1784903170726,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.contraception.2025.110889","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T08:21:38Z","timestamp":1742458898000},"page":"110889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Effects of estetrol\/drospirenone on self-reported physical and emotional premenstrual and menstrual symptoms: Data from the phase 3 clinical trial in the United States and Canada"],"prefix":"10.1016","volume":"147","author":[{"given":"C\u00e9line","family":"Bouchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Kaunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Foidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell D.","family":"Creinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2025.110889_bib1","first-page":"683","article-title":"Work loss associated with increased menstrual loss in the United States","volume":"100","author":"C\u00f4t\u00e9","year":"2002","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.110889_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026186","article-title":"Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women","volume":"9","author":"Schoep","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.contraception.2025.110889_bib3","first-page":"Cd002120","article-title":"Combined oral contraceptive pill for primary dysmenorrhoea","volume":"7","author":"Schroll","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.110889_bib4","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/humrep\/der417","article-title":"The effect of combined oral contraceptives and age on dysmenorrhoea: an epidemiological study","volume":"27","author":"Lindh","year":"2012","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2025.110889_bib5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2147\/IJWH.S297062","article-title":"Management of premenstrual dysphoric disorder: a scoping review","volume":"14","author":"Carlini","year":"2022","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.contraception.2025.110889_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OAJC.S97013","article-title":"Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review","volume":"7","author":"Lete","year":"2016","journal-title":"Open Access J Contracept"},{"key":"10.1016\/j.contraception.2025.110889_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006586.pub4","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","author":"Lopez","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.110889_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm11154634","article-title":"Bleeding patterns of oral contraceptives with a cyclic dosing regimen: an overview","volume":"11","author":"Archer","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.contraception.2025.110889_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/00006842-196811000-00006","article-title":"The development of a menstrual distress questionnaire","volume":"30","author":"Moos","year":"1968","journal-title":"Psychosom Med"},{"key":"10.1016\/j.contraception.2025.110889_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257333","article-title":"A systematic review of the menstrual experiences of university students and the impacts on their education: a global perspective","volume":"16","author":"Munro","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2025.110889_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/13625187.2024.2359117","article-title":"Effects of E4\/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: data from the phase 3 clinical trial in Europe and Russia","volume":"29","author":"Bitzer","year":"2024","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2025.110889_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110889_bib13","unstructured":"World Health Organization. Medical eligibility criteria for contraceptive use. Fifth edition, 2015. Geneva, Switzerland. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789241549158. (accessed September 20, 2024)."},{"key":"10.1016\/j.contraception.2025.110889_bib14","unstructured":"Moos RH. Menstrual Distress Questionnaire [Internet]. Menstrual Distress Questionnaire - Manual. 2010. Available at: \u3008https:\/\/www.mindgarden.com\/menstrual-distress-questionnaire\/351-mdq-manual.html\u3009. (accessed September 20, 2024)."},{"key":"10.1016\/j.contraception.2025.110889_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0191-8869(92)90211-7","article-title":"Factor structure of the Menstrual Distress Questionnaire (MDQ): exploratory and LISREL analyses","volume":"13","author":"Boyle","year":"1992","journal-title":"Pers Individ Dif"},{"key":"10.1016\/j.contraception.2025.110889_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2025.110889_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006586.pub3","article-title":"Oral contraceptives containing drospirenone for premenstrual syndrome","author":"Lopez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2025.110889_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/01.AOG.0000175834.77215.2e","article-title":"Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder","volume":"106","author":"Yonkers","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2025.110889_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.contraception.2010.10.010","article-title":"Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24\/4 regimen","volume":"84","author":"Marr","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110889_bib20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1089\/15246090152543148","article-title":"Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder","volume":"10","author":"Freeman","year":"2001","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1016\/j.contraception.2025.110889_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/0044011-200929020-00001","article-title":"Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone: results of three multicentre trials","volume":"29","author":"Bitzer","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.contraception.2025.110889_bib22","first-page":"35","article-title":"Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being","volume":"7 3","author":"Mansour","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2025.110889_bib23","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)","volume":"94","author":"Apter","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110889_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0010-7824(01)00218-9","article-title":"A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation","volume":"64","author":"Sanders","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2025.110889_bib25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.psyneuen.2016.11.033","article-title":"Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle\u00a0\u2013 a double-blind, placebo-controlled randomized trial","volume":"76","author":"Lundin","year":"2017","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.contraception.2025.110889_bib26","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.contraception.2012.04.010","article-title":"Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women","volume":"86","author":"Hall","year":"2012","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782425000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T01:09:27Z","timestamp":1748740167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782425000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"alternative-id":["S0010782425000800"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2025.110889","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of estetrol\/drospirenone on self-reported physical and emotional premenstrual and menstrual symptoms: Data from the phase 3 clinical trial in the United States and Canada","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2025.110889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Estetra SRL. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110889"}}